Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma : A Translocation-Associated Sarcoma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JCO precision oncology - 5(2021) vom: 25. Nov., Seite 1-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Doshi, Sahil D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B7-H1 Antigen |
|---|
| Anmerkungen: |
Date Completed 28.03.2022 Date Revised 28.03.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1200/PO.20.00201 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335299040 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335299040 | ||
| 003 | DE-627 | ||
| 005 | 20231225225518.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/PO.20.00201 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335299040 | ||
| 035 | |a (NLM)34994591 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Doshi, Sahil D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Benefit From Immune Checkpoint Blockade in Sclerosing Epithelioid Fibrosarcoma |b A Translocation-Associated Sarcoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2022 | ||
| 500 | |a Date Revised 28.03.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a B7-H1 Antigen |2 NLM | |
| 650 | 7 | |a CD274 protein, human |2 NLM | |
| 650 | 7 | |a CD8 Antigens |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a MUC4 protein, human |2 NLM | |
| 650 | 7 | |a Mucin-4 |2 NLM | |
| 700 | 1 | |a Oza, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Remotti, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Remotti, Fabrizio |e verfasserin |4 aut | |
| 700 | 1 | |a Moy, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, Gary K |e verfasserin |4 aut | |
| 700 | 1 | |a Ingham, Matthew |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO precision oncology |d 2017 |g 5(2021) vom: 25. Nov., Seite 1-5 |w (DE-627)NLM273576054 |x 2473-4284 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2021 |g day:25 |g month:11 |g pages:1-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/PO.20.00201 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2021 |b 25 |c 11 |h 1-5 | ||